Innohale Therapeutics
Inhaled Nitric Oxide Delivery Solutions
Health Tech & Life Sciences
Non Active, Jan 2025 ceased to operate
Company Overview
Snapshot
Founded in April 2020 by Dan Rappaport and Yaacov Nitzan, Innohale Therapeutics operates with 1–10 employees. The company is currently in a Pre-Funding stage.
Business overview
Innohale Therapeutics develops advanced inhaled nitric oxide (iNO) delivery solutions. Its core technology focuses on producing iNO from ambient air, aiming to enhance treatment accuracy while reducing costs and logistical burdens. The company serves the healthcare industry, particularly addressing respiratory conditions stemming from various etiologies, including COVID-19, and severe lung infections. Innohale Therapeutics operates within the Health Tech & Life Sciences sector, with a specific focus on medical devices and life support solutions.
Log in to access full profile ›Company Intelligence Q&A
- What is Innohale Therapeutics' primary focus?
- Innohale Therapeutics specializes in developing inhaled nitric oxide (iNO) delivery solutions for treating respiratory conditions and severe lung infections.
- When was Innohale Therapeutics founded?
- Innohale Therapeutics was founded in April 2020.
- Who are the founders of Innohale Therapeutics?
- The company was co-founded by Dan Rappaport and Yaacov Nitzan.
- What is the status of Innohale Therapeutics?
- Innohale Therapeutics is currently non-active, having ceased operations in January 2025.
- What is Innohale Therapeutics' product development stage?
- Innohale Therapeutics' products are in the R&D stage, focusing on developing inhaled nitric oxide delivery solutions.